New drug targets Hard-to-Treat tumors in early trial
NCT ID NCT05707676
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 23 times
Summary
This early-phase study tested a new drug called LB4330 in 40 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system attack cancer cells by targeting a protein called Claudin 18.2. The main goals were to check safety, find the right dose, and see how the body processes the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200120, China
Conditions
Explore the condition pages connected to this study.